LDK278
Total Payments
$254,224
Transactions
4
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $238,942 | 1 | 0 |
| 2017 | $15,282 | 3 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $254,224 | 4 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A BIOMARKER DRIVEN PROTOCOL FOR PREVIOUSLY TREATED ALK-POSITIVE NON-SQUAMOUS NSCLC PATIENTS | Novartis Pharmaceuticals Corporation | $238,942 | 0 |
| PHASE II TRIAL OF TARGETED KINASE FUSION INHIBITION IN UNRESECTABLEE STAGE III/IV BRAF/NRAS WILD-TYPE MELANOMA | Novartis Pharmaceuticals Corporation | $12,255 | 0 |
| A PHASE II MULTI CENTER OPEN LABEL SINGLE ARM STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL LDK378 TREATMENT FOR PATIENTS WITH ALK REARRANGED NON SMALL CELL LUNG CANCER METASTATIC TO THE BRAIN | Novartis Pharmaceuticals Corporation | $2,878 | 0 |
| A PHASE I OPEN LABEL MULTI CENTER SINGLE DOSE STUDY TOEVALUATE THE PHARMACOKINETICS OF LDK378 IN SUBJECTS WITHHEPATIC IMPAIRMENT COMPARED TO SUBJECTS WITH NORMAL HEPATIC FUNCTION | Novartis Pharmaceuticals Corporation | $150.00 | 0 |
Top Doctors Receiving Payments for LDK278
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Orlando, FL | $254,224 | 4 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $254,224
Product Information
- Type Drug
- Total Payments $254,224
- Total Doctors 0
- Transactions 4
About LDK278
LDK278 is a drug associated with $254,224 in payments to 0 healthcare providers, recorded across 4 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $238,942 was paid across 1 transactions to 0 doctors.
The most common payment nature for LDK278 is "Unspecified" ($254,224, 100.0% of total).
LDK278 is associated with 4 research studies, including "A BIOMARKER DRIVEN PROTOCOL FOR PREVIOUSLY TREATED ALK-POSITIVE NON-SQUAMOUS NSCLC PATIENTS" ($238,942).